| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 286.788 | 287.046 | 287.286 | 249.495 | 225.870 | 223.608 | 224.667 | 218.297 | 469.439 | 460.090 |
| Total Income - EUR | 287.161 | 287.592 | 287.977 | 250.141 | 226.280 | 231.117 | 241.422 | 231.065 | 470.730 | 462.497 |
| Total Expenses - EUR | 297.766 | 278.030 | 243.218 | 220.965 | 225.134 | 225.728 | 180.364 | 225.515 | 387.425 | 508.571 |
| Gross Profit/Loss - EUR | -10.606 | 9.562 | 44.759 | 29.176 | 1.146 | 5.389 | 61.058 | 5.550 | 83.305 | -46.075 |
| Net Profit/Loss - EUR | -10.606 | 9.103 | 38.305 | 26.681 | -1.113 | 3.284 | 58.800 | 3.411 | 79.424 | -46.075 |
| Employees | 7 | 9 | 6 | 6 | 6 | 7 | 5 | 4 | 7 | 8 |
Check the financial reports for the company - Nci Genomics S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 51.772 | 32.285 | 32.314 | 20.476 | 13.576 | 9.900 | 8.162 | 8.475 | 10.551 | 8.945 |
| Current Assets | 100.709 | 96.278 | 59.746 | 103.513 | 43.908 | 81.329 | 77.911 | 68.091 | 134.897 | 92.209 |
| Inventories | 1.181 | 680 | 977 | 0 | 2.288 | 2.097 | 1.040 | 2.098 | 8.881 | 3.973 |
| Receivables | 81.753 | 80.752 | 32.251 | 35.634 | 29.716 | 59.957 | 37.119 | 43.697 | 70.145 | 78.415 |
| Cash | 17.775 | 14.845 | 26.519 | 67.879 | 11.904 | 19.275 | 39.752 | 22.297 | 55.870 | 9.821 |
| Shareholders Funds | 36.154 | 44.888 | 82.434 | 107.602 | 25.102 | 27.911 | 58.849 | 3.460 | 82.873 | 36.335 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 116.327 | 83.775 | 9.626 | 16.387 | 32.381 | 35.683 | 15.767 | 74.842 | 65.589 | 68.267 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 27.666 | 11.642 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6210 - 6210" | |||||||||
| CAEN Financial Year |
6201
|
|||||||||
Comments - Nci Genomics S.r.l.